

Evaluation of recombinant *Neospora caninum* antigens purified from silkworm larvae for the protection of *N. caninum* infection in mice

メタデータ	言語: en 出版者: Elsevier 公開日: 2016-06-02 キーワード (Ja): キーワード (En): 作成者: Yoshimoto, Mai, Otsuki, Takahiro, Itagaki, Kohei, Kato, Tatsuya, Kohsaka, Tetsuya, Matsumoto, Yumino, Ike, Kazunori, Park, Enoch Y. メールアドレス: 所属:
URL	http://hdl.handle.net/10297/9421

1 **Evaluation of recombinant *Neospora caninum* antigens**
2 **purified from silkworm larvae for the protection of *N.***
3 ***caninum* infection in mice**

4 Mai Yoshimoto,¹ · Takahiro Otsuki,¹ · Kohei Itagaki,¹ · Tatsuya Kato,^{1,2} · Tetsuya
5 Kohsaka,³ · Yumino Matsumoto,⁴ · Kazunori Ike,⁴ · Enoch Y. Park^{1,2*}

6
7 *Laboratory of Biotechnology, Department of Applied Biological Chemistry, Faculty of*
8 *Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan,¹*
9 *Laboratory of Biotechnology, Research Institute of Green Science and Technology,*
10 *Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan,² Laboratory of*
11 *Animal Reproduction & Physiology, Department of Applied Biological Chemistry,*
12 *Faculty of Agriculture, Shizuoka University, Suruga-ku, Shizuoka 422-8529, Japan,³*
13 *Laboratory of Veterinary Parasitology, Nippon Veterinary and Life University,*
14 *Musashino, Tokyo, 180-8602, Japan⁴*

15

* Corresponding author at: *Laboratory of Biotechnology, Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan. Tel. & Fax: +81-54-238-4887*
E-mail: park.enoch@shizuoka.ac.jp (E.Y. Park)

16 **ABSTRACT**

17 Three antigens (NcSAG1, NcSRS2 and NcMIC3) from *Neospora caninum* (silkworm)
18 larvae were expressed using the BmNPV bacmid system and purified from the
19 hemolymph. From 20 silkworm larvae, 1.5, 1.2 and 1.4 mg of purified recombinant
20 NcSAG1, NcSRS2 and NcMIC3 were obtained, respectively. When each purified
21 recombinant antigen was immunized with Freund's incomplete adjuvant (FIA) to mice,
22 recombinant NcSAG1 induced a Th2 immune response in immunized mice and
23 produced a SAG1-specific antibody. In the experiment where NcSAG1-immunized
24 mice were challenged with *N. caninum*, the cerebral *N. caninum* burden was
25 significantly reduced compared with that of either the FIA- or PBS-immunized mice.
26 Recombinant NcSRS2 or NcMIC3 induced both Th1 and Th2 immune responses, but
27 NcMIC3-immunization did not induce significant production of NcMIC3-specific
28 antibodies. These results suggest that the silkworm can produce recombinant antigens
29 of *N. caninum*, which can be used as a recombinant vaccine against *N. caninum*.

30 **[Key words:** *N. caninum*, antigen, subunit vaccine, BmNPV bacmid, silkworm]

31 **INTRODUCTION**

32 *Neospora caninum*, an intracellular apicomplexan parasite that is closely related to
33 *Toxoplasma gondii*, causes abortion, stillbirth and congenital infection in cattle (1,2).
34 This parasite can transmit to cattle by oral ingestion of oocysts excreted by a canid host
35 (horizontal transmission) and from an infected cow to its fetus (vertical transmission).
36 Neosporosis is a major problem for the livestock industry because of calf mortality and
37 loss of milk production. The elimination of infected cattle from the herd by culling is a
38 safe method to control the disease, but this method requires the identification of
39 infected animals in the herd. No chemotherapeutic agent is available commercially.
40 Vaccine treatment is favorable to prevent this infection in cattle because there is no risk
41 of long lasting residues in the milk and meat. As vaccine candidates, live vaccines,
42 inactivated parasite vaccines and native or recombinant subunit vaccines have been
43 investigated (3).

44 Immunization with live parasite has provided promising results to protect against
45 fetal death in cattle. In the case of toxoplasmosis, a live vaccine (Toxovac™) for sheep
46 composed of a non-persistent strain *T. gondii* S48 is commercially available in Europe
47 and New Zealand (4). Immunization with a naturally isolated less-virulent parasite, *N.*
48 *caninum* Nowra, protected adult cattle and their fetuses from *N. caninum* infection
49 (5,6). Other live attenuated parasites were also isolated (7). However, immunization
50 with live parasite vaccines has serious disadvantages from a safety point of view, in
51 addition to high production costs and unfavorable product stability. Inactivated
52 parasites are regarded as vaccine candidates. Protection against fetal infection in cattle
53 by killed parasites was observed, but the abortion rate was still approximately 50% (8).

54 Additionally, killed parasite vaccines are not as cost-effective as live attenuated
55 vaccines.

56 Subunit vaccines are a promising candidate for the prevention of *N. caninum*
57 infection in cattle as they are safer and less costly. CoxAbic[®] is composed of
58 affinity-purified gametocyte antigens from *Eimeria maxima* and is commercially
59 available as a native subunit vaccine against coccidiosis in hens (9). However, no
60 recombinant subunit vaccine against *N. caninum* is commercially available, but this
61 type of vaccine is currently being investigated to protect cattle from parasite infection
62 (3,10). As a recombinant subunit vaccine, proteins on the surface of parasites, proteins
63 in micronemes, rhoptry proteins, dense granule proteins and proteins in the
64 parasitophorous vacuole membrane of *N. caninum* have been investigated (3).

65 In this study, *N. caninum* surface antigen 1 (NcSAG1), SAG1-related sequence 2
66 (NcSRS2) and microneme protein 3 (NcMIC3) were expressed into the hemolymph of
67 silkworm larvae and purified. NcSAG1 and NcSRS2 are two major surface antigens of
68 *N. caninum* tachyzoites (11,12). The invasion by tachyzoites into hosts begins via the
69 interaction between these antigens and the membrane of host cells (13). Therefore,
70 these antigens are recognized as a promising recombinant subunit vaccine candidate
71 (14,15). In addition, MIC proteins also seem to interact with the receptors of host cells
72 (16) and have been investigated as a vaccine candidate as well (17,18). Each
73 recombinant antigen purified from silkworm hemolymph was immunized into mice,
74 and the prevention of *N. caninum* cerebral infection in mice was evaluated by *N.*
75 *caninum* real-time PCR.

76

77 **MATERIALS AND METHODS**

78 **Materials** Restriction enzymes and modification enzymes were purchased from
79 Nippon gene (Tokyo, Japan), Takara-bio (Shiga, Japan), and Toyobo (Osaka, Japan).
80 Other reagents were purchased from Wako Pure Chemical Ind. Ltd. (Osaka, Japan) and
81 Sigma Aldrich Japan (Tokyo, Japan). Oligonucleotides were purchased from Operon
82 Biotechnology (Tokyo, Japan). *N. caninum* Nc-Liverpool isolate (Nc-Liv; ATCC No.
83 50845), *N. caninum* Nc-1 genomic DNA and Vero cells (ATCC No. CCL-81) were
84 purchased from American Type Culture Collection (Rockville, MD, USA). Female
85 BALB/c mice (6 weeks of age) were purchased from Japan SLC, Inc. (Shizuoka,
86 Japan)

87 **Construction of recombinant BmNPV bacmids** For NcSAG1 expression in
88 silkworm larvae, BmNPV CP⁻ Chi⁻-bx-FLAGHRV3C-SAG1 bacmid was constructed
89 as described previously (19). In the case of NcSRS2, the *srs2* gene (54-376 aa,
90 NcSRSNC) lacking an N-terminal signal peptide-coding sequence and C-terminal
91 domain was amplified by PCR using a primer set (Table 1). The amplified truncated
92 *srs2* gene was replaced with the full *srs2* gene in recombinant pDEST8 constructed as
93 previously described (19). The constructed recombinant pDEST8 vector in this study
94 has a truncated *srs2* gene connected with the signal sequence of bombyxin from *B.*
95 *mori*. This constructed recombinant pDEST8 vector was transformed into *Escherichia*
96 *coli* BmDH10Bac CP⁻Chi⁻ (20), and the BmNPV CP⁻ Chi⁻-bx-FLAGSR2NC bacmid
97 was obtained.

98 The NcMIC3 gene lacking an N-terminal signal peptide-coding sequence was

99 amplified by a primer set (Table 1). The amplified gene was inserted into the pET52b
100 vector at the *KpnI-NotI* site. Next, each gene was amplified by PCR using a
101 CACC-bx-FLAG-HRV3C primer and the NcMIC3 reverse primer (Table 1). The
102 amplified gene was composed of the bx signal peptide sequence, a FLAG peptide
103 sequence, a human rhinovirus 3C protease cleavage site sequence, and each protein
104 coding sequence. Each amplified gene was inserted into a pENTR/D/TOPO (Life
105 Technologies Japan, Tokyo, Japan) vector by the TOPO reaction. The *mic3* gene was
106 moved from the constructed pENTR vector to pDEST8 by the GATEWAY LR reaction
107 (Life Technologies Japan). The constructed pDEST vector was transformed into *E. coli*
108 BmDH10Bac CP-Chi⁻ and the BmNPV CP-Chi⁻-bx-FLAGMIC3 bacmid was obtained.
109 All antigens were expressed as a fusion protein with the bx signal peptide, a FLAG
110 peptide, and a human rhinovirus 3C protease cleavage site.

111 **Expression of recombinant *N. caninum*-antigens and purification** Each
112 recombinant BmNPV bacmid DNA injection into silkworm larvae and rearing
113 silkworm larvae was performed according to the previous report (21). Hemolymph was
114 collected from silkworm larvae by cutting the prolegs, and 1-phenyl-2-thiourea was
115 added into the collected hemolymph at 5 mM to prevent melanization. Collected
116 hemolymph was centrifuged at 10000 × g for 15 min to remove hemocytes and debris,
117 and its supernatant was used as the hemolymph sample.

118 To purify expressed recombinant *N. caninum*-antigens, 1 ml of anti-FLAG M2
119 antibody agarose (Sigma Aldrich Japan) was packed in an empty column and
120 equilibrated with Tris-buffered saline (TBS; pH 7.5). Hemolymph was diluted 5-fold
121 with TBS and loaded onto the anti-FLAG M2 antibody agarose column. The column

122 was washed with 10 ml of TBS after loading the hemolymph and proteins were eluted
123 with 8 ml of glycine-HCl buffer (pH 3.5). Every fraction of the 1 ml eluent was
124 collected.

125 **SDS-PAGE and Western blot** Proteins were separated by sodium dodecyl
126 sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10% or 12% acrylamide
127 gels. After SDS-PAGE, proteins were electrotransferred onto a polyvinylidene fluoride
128 (PVDF) membrane using the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad,
129 Hercules, CA, USA). After blocking in 5% skimmed milk in TBS containing 0.1%
130 Tween 20 (TBST), the membrane was incubated for 1 h in 1:10000 mouse anti-FLAG
131 M2 antibody (Sigma-Aldrich Japan). The membrane was washed with TBST and
132 incubated for 1 h in 1:20000 anti-mouse IgG antibody labeled with horseradish
133 peroxidase (GE Healthcare, Buckinghamshire, UK). Detection was performed with
134 ECL Plus Western blotting reagent (GE Healthcare). Specific protein bands were
135 detected by Fluor-S MAX MultiImager (Bio-Rad, Hercules, CA, USA).

136 **Immunization of recombinant *N. caninum*-antigens in mice and challenge of *N.***
137 ***caninum* tachyzoites into immunized mice** All mice used in the present study
138 were treated under the guiding principles for the care and use of research animals as
139 outlined by the Nippon Veterinary and Life Science University, Japan. Female BALB/c
140 mice were housed under conventional day/night conditions. At the age of 7 weeks,
141 mice were randomly distributed into 6 experimental groups of 12 mice each. Groups
142 1–5 were immunized intramuscularly with 10 µg of each purified recombinant *N.*
143 *caninum*-antigen or PBS in Freund's incomplete adjuvant (FIA, adjuvant control
144 group). Mice in Group 6 received PBS alone (infection control group). Immunization

145 was performed three times every two weeks. After immunization, 3.84×10^6 of *N.*
146 *caninum* Nc-Liverpool was injected intraperitoneally into immunized mice and they
147 were reared for 5 weeks. Blood and brains were collected and serum was prepared by
148 centrifuging the blood at $1,000 \times g$.

149 **Enzyme-linked immunosorbent assay (ELISA)** The crude extract of *N.*
150 *caninum* (250 ng of protein/well) were immobilized onto a 96-well plate by incubation
151 at 37°C for 1 h. The supernatant was removed and 2% skimmed milk in TBST was
152 added into each well and incubated for 1 h. The skimmed milk solution was removed
153 and 100 μ l of diluted mice serum was added to each well. After incubation at room
154 temperature for 1 h, the antibody solution was removed and each well was washed
155 with TBS. Anti-mouse IgG antibody-HRP (GE Healthcare) diluted 5000-fold with
156 TBST was added to each well and incubated at room temperature for 1 h. Each well
157 was washed with TBST and then the HRP reaction was carried out. One hundred
158 microliters of substrate (0.1 mg/ml 3,3',5,5'-tetramethylbenzidine in 100 mM sodium
159 acetate [pH 6.0] with 0.2% [v/v] of 30% hydrogen peroxide) was added to each well
160 and incubated at room temperature until a blue color developed in each well. The HRP
161 reaction was stopped by the addition of 50 μ l 1N H₂SO₄ solution and the absorbance of
162 each well was measured at 450 nm.

163 To confirm IgG subclasses, the crude extract of *N. caninum* (250 ng of
164 protein/well) was immobilized in wells in a 96-well plate blocked using 2% skimmed
165 milk in TBST. After washing each well with TBST, serum from antigen-immunized
166 mice was added to each well. HRP-conjugated anti-mouse IgG1 and IgG2a antibodies
167 (Santa Cruz Biotechnology, Dallas, TX, USA) were used as secondary antibodies. The

168 HRP reaction was the same as that used in the ELISA method described above.

169 **Indirect immunofluorescence detection of *N. caninum*** Vero cells were
170 cultivated in T-25 flasks at confluence using MEM medium (Life Technologies Japan)
171 supplemented with 50 U/ml penicillin-streptomycin (Life Technologies Japan) and 5%
172 horse serum (Life Technologies Japan). Medium was replaced with MEM medium
173 supplemented with 50 U/ml penicillin-streptomycin and 1% horse serum and cells
174 were cultivated for two weeks after *N. caninum* infection. Cells were collected and
175 disrupted by flushing through a 26 s needle several times. The cell homogenate was
176 filtered through a 5 µm-filter to remove debris, and the filtrate was used as a parasite
177 solution.

178 For indirect immunofluorescence detection of *N. caninum*, *N. caninum* cells
179 suspended in PBS were immobilized onto an APS-coated glass slide (Matsunami Glass
180 Ind., Osaka, Japan) and washed three times with PBS. Parasites were fixed with 4%
181 paraformaldehyde and blocked with 4% BSA in PBS supplemented with 25 mM
182 NH₄Cl. After washing with PBS three times, serum from immunized mice, which was
183 diluted 200-fold with 2% BSA in PBS, was added to glass slides and incubated at room
184 temperature for 1 h. The slides were washed three times with PBS, and parasites were
185 incubated at room temperature for 1 h with anti-mouse IgG conjugated with Alexa
186 Fluor 594 diluted 200-fold (Jackson ImmunoResearch, Laboratories, West Grove, PA,
187 USA). In addition, parasites were incubated with 1 µg/ml DAPI for nuclear staining.
188 Fluorescence was observed using a confocal laser scanning microscope (LSM700, Carl
189 Zeiss Japan, Tokyo, Japan).

190 **Semi-quantitative real-time PCR using *N. caninum* DNA from immunized**
191 **mouse brains** DNA was extracted from the brains using the DNeasy Blood &
192 Tissue Kit (Qiagen, Tokyo, Japan). Semi-quantitative real-time PCR was performed
193 using a *N. caninum*-specific primer set (Table 1) and 2×Full Velocity SYBR Green
194 QPCR Master Mix (Agilent Technologies, Santa Clara, CA, USA). Seven hundred
195 nanograms of extracted DNA were used as a template. PCR conditions were as
196 follows: 1st cycle 95°C 5 min, 2nd cycle 95°C 10 s, 60°C 30 s, 80 cycles. The DNA
197 fragment amplified by semi-quantitative PCR was verified as a single band by melting
198 curve analysis and agarose gel electrophoresis.

199 **Measurement of cytokines** Cytokine levels were measured in splenocytes
200 seeded at 1×10^6 cells per well in Hybridoma-SFM medium (Life Technologies Japan)
201 containing 10% FCS with or without 10 µg/ml of each recombinant *N. caninum*
202 antigen or Concanavalin A (ConA; Sigma-Aldrich Japan, positive control) in 24-well
203 microplates (Corning Incorporated, Corning, NY, USA). Microplates were kept at
204 37 °C for 48 h in a 5% CO₂ atmosphere. After stimulation, interferon-γ (IFN-γ) and
205 interleukin 4 (IL-4) levels in the culture supernatant were measured using IFN- γ and
206 IL-4 enzyme-linked immunoassay (ELISA) kits (Thermo Scientific, Rockford, IL,
207 USA), respectively, according to the manufacturer's instructions (assay range: 37 to
208 3700 pg/ml, sensitivity: <10 pg/ml). The amount of secreted cytokines was calculated
209 using a standard cytokine curve ran on the same immunoplate.

210 **RESULTS AND DISCUSSION**

211 **Expression of NcSAG1, NcSRS2 and NcMIC3 in silkworm larvae and**

212 **purification** NcSAG1 expression was carried out using the same construct (19) in
213 silkworm larvae. NcSRS2 (54-376 aa) lacking its N-terminal signal peptide and
214 C-terminal domain was expressed into silkworm hemolymph by fusion with the bx
215 signal peptide at its N-terminus. MIC3 (26-362 aa), whose signal peptide was removed,
216 was also expressed into silkworm hemolymph by fusion with the bx signal peptide at its
217 N-terminus. Each antigen was also fused with a FLAG peptide and purified from
218 silkworm hemolymph by anti-FLAG M2 antibody agarose gel. All three antigens were
219 detected by their estimated molecular weight (32 kDa for NcSAG1, 36 kDa for
220 NcSRS2, and 41 kDa for NcMIC3, Fig. 1). In a previous paper, recombinant NcSAG1
221 expressed in silkworms was also observed at this estimated molecular weight (19).
222 These results suggest that these antigens expressed in silkworms may be modified
223 post-translationally, and in fact, NcSAG1, NcSRS2 and NcMIC3 have 4, 3 and 1
224 putative N-glycosylation sites, respectively. However, modification by N-glycosylation
225 has not been investigated. Native NcSRS2 in *N. caninum* tachyzoites and recombinant
226 NcSRS2 expressed in insect cells were observed at approximately 42 kDa (22,23).
227 Recombinant NcSAG1 and NcSRS2 were observed as an almost single band, but
228 recombinant NcMIC3 was observed with several minor bands. By Western blot
229 analysis, these minor bands came from NcMIC3 (data not shown). From 20 silkworm
230 larvae, 1.5, 1.2 and 1.4 mg of purified recombinant NcSAG1, NcSRS2 and NcMIC3
231 were obtained, respectively. Previously, 370 μ g of NcSRS2 was obtained from 17
232 silkworm larvae (19). In this study, an approximately 2.7-fold higher yield of NcSRS2
233 was obtained than that of the previous paper. NcSRS2 has a glycosphosphoinositol
234 (GPI) anchor at its C-terminus (23) and a GPI anchor in the recombinant NcSRS2 was
235 also observed in silkworm larvae (24). This suggests that the deletion of the C-terminal

236 domain coding its GPI anchor signal peptide enhances the expression of NcSRS2 in
237 the hemolymph of silkworms because the expressed NcSRS2 might be more robustly
238 extracellularly secreted into silkworm hemolymph.

239 **Immunization of each *N. caninum* antigen to mice and challenge of *N.***
240 ***caninum* tachyzoites** Serum of mice immunized by recombinant NcSAG1 or
241 NcSRS2 emulsified with FIA showed reactivity to the crude extract of *N. caninum*, but
242 mice immunized by recombinant NcMIC3 emulsified with FIA showed only slight
243 reactivity to the *N. caninum* crude extract (Fig. 2A). Serum from mice immunized with
244 recombinant NcMIC3 showed the reactivity to recombinant NcMIC3 (data not shown).
245 In the case of FIA and PBS, antibodies to *N. caninum* were not detected in serum from
246 mice even after the challenge of *N. caninum* tachyzoites. It indicates that *N. caninum*
247 tachyzoite challenge hardly elicited antibodies to *N. caninum*, compared to
248 recombinant NcSAG1 and NcSRS2 immunization and NcMIC3 is not favorable as a
249 subunit vaccine candidate to *N. caninum* tachyzoites. In sera from mice immunized
250 with recombinant NcSAG1 and NcSRS2, IgG1 production was predominant compared
251 to IgG2a (Fig. 2B). To confirm the reactivity of antibodies in the serum from mice
252 immunized by recombinant NcSAG1 or NcSRS2, *N. caninum* tachyzoites were stained
253 using these sera via indirect immunofluorescence microscopy (Fig. 2C). Both sera
254 from mice immunized by recombinant NcSAG1 or NcSRS2 stained *N. caninum*,
255 indicating that the immunization of each antigen purified from silkworm hemolymph
256 produced the antibodies to each antigen in mice. *N. caninum* tachyzoites were not
257 significantly stained by serum from mice immunized by recombinant NcMIC3 (data
258 not shown). *N. caninum* tachyzoites have micronemes which house several MIC

259 proteins (3). MIC3 also localizes at the apical tip within the *N. caninum* microneme
260 (25). These results suggest that the produced NcMIC3-specific antibody has only a low
261 reactivity to native NcMIC3 in *N. caninum* tachyzoites.

262 **Challenge of *N. caninum* tachyzoites into immunized mice** After challenge of
263 *N. caninum* tachyzoites into mice immunized with each recombinant antigen, the
264 cerebral *N. caninum* burden was measured by semi-quantitative real-time PCR using *N.*
265 *caninum*-specific primers. The cerebral parasite burden in mice was decreased
266 significantly by immunization with NcSAG1 compared with only FIA and PBS (Fig.
267 3).

268 **Cytokines** The levels of secreted IFN- γ and IL-4 in splenocytes from mice
269 immunized with each recombinant antigen were measured by stimulation with each
270 antigen or ConA. Splenocytes from mice immunized with recombinant NcSAG1
271 predominantly produced IL-4 and IgG1 (Fig. 2B), but those from mice immunized
272 with recombinant NsSRS2 produced both IFN- γ and IL-4 (Fig. 4), and IgG1 and low
273 level of IgG2a (Fig. 2B). These results indicate that recombinant NcSAG1 induced a
274 Th2 immune response with FIA in mice, and recombinant NsSRS2, induced Th1 and
275 Th2 immune responses. In the case of recombinant NcMIC3, productions of IFN- γ and
276 IL-4 were confirmed (Fig. 4), but those of IgG1 and IgG2a did not. In this experiment,
277 the immunization by recombinant NcMIC3 was very low reactivity compared to those
278 of other antigens (Fig. 2A). This is the reason why the recombinant NcMIC3 produced
279 low level of IgG subclass.

280 In case of an immunization with native NcSRS2 purified from *N. caninum*-infected

281 Vero cells elicited only a Th2 immune response with FIA and reduced the vertical
282 transmission of *N. caninum* in mice (22). In addition, native NcMIC3 also induced
283 only Th2-type IgG1 antibody production in mice (17). In non-pregnant mice, the Th2
284 immune response seems to be effective in preventing the cerebral *N. caninum* infection.
285 To prevent the vertical transmission of *N. caninum* in pregnant mice and cows, a
286 balanced Th1/Th2 immune response is needed (3). Antigens from *N. caninum* purified
287 from silkworm hemolymph elicited both a Th1 and Th2 immune response in
288 immunized mice, suggesting that recombinant antigens purified from silkworm
289 hemolymph are likely to be vaccine candidates that could prevent the horizontal and
290 vertical transmission of *N. caninum*.

291 Recombinant NcSAG1 or NcSRS2 expressed in *E. coli* significantly reduced the
292 cerebral neosporosis in mice by immunization (26). Recombinant NcMIC3 expressed
293 in *E. coli* induced an IgG1/IgG2a antibody response in mice with ribi adjuvant, but did
294 not IFN- γ , indicating Th2 immune response was predominant in cattle immunization
295 (27). Even though the parasite burden was reduced in brain tissues, recombinant
296 antigens expressed in *E. coli* with immune stimulating complexes failed to prevent the
297 vertical transmission of *N. caninum* in pregnant cattle by experimental intravenous
298 challenge (27). Further research should investigate the effectiveness of recombinant
299 antigens expressed in *E. coli* and silkworms as a recombinant subunit vaccine in both
300 mice and cattle. This study shows that it is possible to use silkworm larvae to produce
301 effective recombinant *N. caninum* antigens for this parasite infection in mice.
302 Simultaneous immunization with recombinant antigens of *N. caninum* with DNA
303 vaccines possessing the antigen genes of *N. caninum* may enhance the induction of

304 immune responses to *N. caninum* in mice (18,26). In addition, the Th1 immune
305 response can be induced by an oil-in-water emulsion with bitter ground extract (28).

306 In this study, three *N. caninum* antigens (NcSAG1, NcARA2 and NcMIC3) were
307 expressed in silkworm larvae using the BmNPV bacmid system and purified from
308 silkworm hemolymph. From 20 silkworm larvae, 1.5, 1.2 and 1.4 mg of recombinant
309 NcSAG1, NcSRS2 and NcMIC3 were obtained, respectively. The immunization of
310 mice with recombinant NcSAG1 induced a predominantly Th2 immune response and
311 significantly reduced the cerebral *N. caninum* infection. In addition, the immunization
312 of mice with recombinant NcSRS2 provoked Th1 and Th2 immune responses and
313 reduced the cerebral *N. caninum* infection although not significantly. Silkworm larvae
314 can produce recombinant antigens of *N. caninum*, which can be used as a recombinant
315 subunit vaccine against *N. caninum* infection.

316 **ACKNOWLEDGMENT**

317 This work was supported by Grant-in-Aid for Scientific Research (A) Grant No.
318 22248009 from the Ministry of Education, Culture, Sports, Science and Technology,
319 Japan.

320 **References**

- 321 1. **Dubey, J. P., Schares, G., and Ortega-Mora, L. M.:** Epidemiology and control
322 of neosporosis and *Neospora caninum*. Clin. Microbiol. Rev., **20**, 323–367
323 (2007).
- 324 2. **Goodswen, S. J., Kennedy, P. J., and Ellis, J. T.:** A review of the infection,

- 325 genetics, and evolution of *Neospora caninum*: From the past to the present. Infect.
326 Genet. Evol., **13**, 133–150 (2013).
- 327 3. **Monney, T., Hemphill, A.:** Vaccines against neosporosis: What can we learn
328 from the past studies? Exp. Parasitol., **140**, 52–70 (2014).
- 329 4. **Buxton, D.:** Toxoplasmosis: The first commercial vaccine. Parasitol., Today **9**,
330 335–337 (1993).
- 331 5. **Williams, D. J., Guy, C. S., Smith, R. F., Ellis, J., Björkman, C., Reichel, M.**
332 **P., Trees, A. J.:** Immunization of cattle with live tachyzoites of *Neospora*
333 *caninum* confers protection against fetal death. Infect. Immun., **75**, 1343–1348
334 (2007).
- 335 6. **Weber, F. H., Jackson, J. A., Sobecki, B., Choromansky, L., Olsen M.,**
336 **Meinert, T., Frank, R., Reichel, M. P., Ellis, T. J.:** On the efficacy and safety
337 of vaccination with live tachyzoites of *N. caninum* for prevention of
338 *Neospora*-associated fetal loss in cattle. Clin. Vaccine Immunol., **20**, 99–105
339 (2013).
- 340 7. **Regidor-Cerrillo, J., Gomez-Bautista, M., Pereira-Bueno, J., Aduriz, G.,**
341 **Navarro-Lozano, V., Risco-Castillo, V., Fernandez-Garcia, A, Pedraza-Diaz,**
342 **Z, Ortega-Mora L. M.:** Isolation and genetic characterization of *Neospora*
343 *caninum* from asymptomatic calves. Parasitology, **135**, 1651–1659 (2008).
- 344 8. **Romero, J. J., Pérez, E., Frankena, K.:** Effect of a killed whole *Neospora*
345 *caninum* tachyzoite vaccine on the crude abortion rate of Costa Rican dairy cows
346 under field conditions. Vet. Parasitol., **123**, 149–159 (2004).
- 347 9. **Sharman, P. A., Smith, N. C., Wallach, M. G., Katrib, M.:** Chasing the golden
348 egg: Vaccination against poultry coccidiosis. Parasite Immunol., **32**, 590–598

- 349 (2010).
- 350 10. **Monney, T., Debache, K., Hemphill, A.:** Vaccines against a major cause of
351 abortion in cattle, *Neospora caninum* infection. *Animals*, **1**, 306–325 (2011).
- 352 11. **Hemphill, A.:** Subcellular localization and functional characterization of
353 Nc-p43, a major *Neospora caninum* tachyzoite surface protein. *Infect. Immun.*, **64**,
354 4279–4287 (1996).
- 355 12. **Nishikawa, Y., Xuan, X., Nagasawa, H., Igarashi, I., Fujisaki, K., Otsuka, H.,**
356 **Mikami, T.:** Monoclonal antibody inhibition of *Neospora caninum* tachyzoite
357 invasion into host cells. *Int. J. Parasitol.*, **30**, 51–58 (2000).
- 358 13. **Hemphill, A., Gottstein, B., Kaufmann H.:** Adhesion and invasion of bovine
359 endothelial cells by *Neospora caninum*. *Parasitology*, **112**, 183–197 (1996).
- 360 14. **Pinitkiatisakul, S., Friedman, M., Wikman, M., Mattsson, J.G.,**
361 **Lövgren-Bengtsson, K., Ståhl, S., Lundén, A.:** Immunogenicity and protective
362 effect against murine cerebral neosporosis of recombinant NcSRS2 in different
363 iscom formulations. *Vaccine*, **25**, 3658–3668 (2007).
- 364 15. **Zhang, G., Huang, X., Boldbaatar D., Battur, B., Battsetseg, B., Zhang, H.,**
365 **Yu, L., Li, Y., Luo, Y., Cao, S., Goo, Y.K., Yamagishi, J., Zhou, J., Zhang, S.,**
366 **Suzuki, H., Igarashi, I., Mikami, T., Nishikawa, Y., Xuan, X.:** Construction of
367 *Neospora caninum* stably expressing TgSAG1 and evaluation of its protective
368 effects against *Toxoplasma gondii* infection in mice. *Vaccine*, **28**, 7243–7247
369 (2010).
- 370 16. **Hemphill, A., Debache, K., Monney, T., Schorer, M., Guionaud, C., Alaeddine,**
371 **F., Mueller, N., Mueller, J.:** Proteins mediating the *Neospora caninum*-host cell
372 interaction as targets for vaccination. *Front. Biosci. (Elite Ed)*, **5**, 23–36 (2013).

- 373 17. **Cannas, A., Naguleswaran, A., Müller, N., Gottstein, B., Hemphill, A.:**
374 Reduced cerebral infection of *Neospora caninum*-infected mice after vaccination
375 with recombinant microneme protein NcMIC3 and ribi adjuvant. *J. Parasitol.*, **89**,
376 44–50 (2003).
- 377 18. **Debache, K., Alaeddine, F., Guionaud, C., Monney, T., Müller, N., Strohbusch,**
378 **M., Leib, S.L., Grandgirard, D., Hemphill, A.:** Vaccination with recombinant
379 NcPOP2 combined with recombinant NcMIC1 and NcMIC3 reduces cerebral
380 infection and vertical transmission in mice experimentally infected with *Neospora*
381 *caninum* tachyzoits. *Int. J. Parasitol.*, **39**, 1373–1384 (2010).
- 382 19. **Otsuki, T., Dong, J., Kato, T., Park, E. Y.:** Expression, purification and
383 antigenicity of *Neospora caninum*-antigens using silkworm larvae targeting for
384 subunit vaccines. *Vet. Parasitol.*, **192**, 284–287 (2013).
- 385 20. **Park, E.Y., Abe, T., Kato, T.:** Improved expression of fusion protein using a
386 cysteine-protease- and chitinase-deficient *Bombyx mori* (silkworm) multiple
387 nucleopolyhedrovirus bacmid in silkworm larvae. *Biotechnol. Appl. Biochem.*, **49**,
388 135–140 (2008).
- 389 21. **Park, E. Y., Kageshima, A., Kwon, M.S., Kato, T.:** Enhanced production of
390 secretory beta1,3-N-acetylglucosaminyltransferase 2 fusion protein into
391 hemolymph of *Bombyx mori* larvae using recombinant BmNPV bacmid integrated
392 signal sequence. *J. Biotechnol.*, **129**, 681–688 (2007).
- 393 22. **Haldorson, G. J., Mathison, B. A., Weinberg, K., Conrad, P. A., Dubey, J. P.,**
394 **Trees, A. J., Yamane, I., Baszler, T. V.:** Immunization with native surface
395 protein NcSRS2 induced a Th2 immune response and reduces congenital
396 *Neospora caninum* transmission in mice. *Int. J. Parasitol.*, **35**, 1407–1415 (2005).

- 397 23. **Nishikawa, Y., Tragoolpua, K., Makala, L., Xuan, X., Nagakawa, H.:**
398 *Neospora caninum* NcSRS2 is a transmembrane protein that contains a
399 glycosylphosphatidylinositol anchor in insect cells. *Vet. Parasitol.*, **109**, 191–201
400 (2002).
- 401 24. **Deo V. K., Yoshimatsu, K., Otsuki, T., Dong, J., Kato, T., Park, E. Y.:**
402 Display of *Neospora caninum* surface protein related sequence 2 on Rous
403 sarcoma virus-derived gag protein virus-like particles. *J. Biotechnol.*, **165**, 69–75
404 (2013).
- 405 25. **Naguleswaran, A., Cannas, A., Keller, N., Vonlaufen, N., Schares, G.,**
406 **Conraths, F. J., Björkman, C., Hemphill, A.:** *Neospora caninum* microneme
407 protein MIC3: secretion, subcellular localization, and functional involvement in
408 host cell interaction. *Infect. Immun.*, **69**, 6483–6494 (2001).
- 409 26. **Cannas, A., Naguleswaran, A., Müller, N., Gottstein, B., Hemphill, A.:**
410 Vaccination of mice against experimental *Neospora caninum* infection using
411 NcSAG1- and NcSRS2-based recombinant antigens and DNA vaccines.
412 *Parasitology*, **126**, 303–312 (2003).
- 413 27. **Hecker, Y. P., Cóceres, V., Wilkowsky, S. E., Ortiz, J. M. J., Morrell, E. L.,**
414 **Verna, A. E., Ganuza, A., Cano, D. B., Lischinsky, L., Ángel, S. O., Zamorano,**
415 **P., Odeón, A. C., Leunda, M. R., Campero, C. M., Morein, B., Moore, D. P.:**
416 A *Neospora caninum* vaccine using recombinant proteins fails to prevent foetal
417 infection in pregnant cattle after experimental intravenous challenge. *Vet.*
418 *Immunol. Immunopathol.*, **162**, 142–153 (2014).
- 419 28. **Uchida M., Nagashima, K., Akatsuka, Y., Murakami, T., Ito, A., Imai, S., Ike,**
420 **K.:** Comparative study of protective activities of *Neospora caninum* bradyzoite

421 antigens, NcBAG1, NcBSR4, NcMAG1, and NcSAG4, in a mouse model of
422 acute parasitic infection. *Parasitol. Res.*, **112**, 655-663 (2013).
423

424 **TABLE 1.** Primers

	5'– 3'
NcSRS2NC-F	TATGGTACCGAGCGCCGTTCAAGTCGGAA
NcSRS2NC-R	TATGAGCTCTTATCCTCTTAACACGGGGGA
NcMIC3-F	TATGGTACCGATTGACTGTTCAGAAA
NcMIC3-R	TATGCGGCCGCTTATCGAGCCGTTCCGCAT
CACC-bx-FLAG	CACCATGAAGATACTCCTTGCTATTGCATTAATGTTGTCAA
-HRV3C	CAGTAATGTGGGTGTCAACAGACTACAAGGATGACGATGA CAAGGGTGCACCTTGAAGTCCTCTTTCAG
NC-F	GTGAGAGGTGGGATACG
NC-R	GTCCGCTTGCTCCCTA

425

426 **Figure legends**


427 **FIG. 1.** SDS-PAGE of recombinant *N. caninum* antigens purified from silkworm
428 hemolymph. Each recombinant antigen was expressed in silkworm larvae and purified
429 from silkworm hemolymph using anti-FLAG M2 antibody agarose. SDS-PAGE gels
430 were stained with Coomassie Brilliant Blue.



431 **FIG. 2.** (A) Antibody responses in mice immunized with each antigen before (white
432 bars) and after (grey bars) the *N. caninum* challenge. Female BALB/c mice were
433 immunized intramuscularly with 10 µg of each purified recombinant antigen or PBS in
434 Freund's incomplete adjuvant three times every two weeks. After immunization, $3.84 \times$
435 10^6 of *N. caninum* Nc-Liv was injected intraperitoneally into immunized mice and
436 reared for 5 weeks. (B) IgG subclass measurement of serum from mice immunized
437 with each recombinant antigen. (C) Indirect immunofluorescent microscopy of *N.*
438 *caninum* tachyzoites using the serum of mice immunized with recombinant NcSAG1
439 or NcSRS2. The nuclei of *N. caninum* tachyzoites were stained with DAPI. Scale bars
440 indicate 5 µm.


441 **FIG. 3.** Quantification of cerebral *N. caninum* amount in mice ($n = 5$) immunized with
442 each recombinant antigen using semi-quantitative real-time PCR. DNA was extracted
443 from the brain of mice using a DNeasy Blood and Tissue kit. Semi-quantitative
444 real-time PCR was performed using extracted DNA (500 ng) and *N. caninum*-specific
445 primers. Significance differences between two groups were observed statistically by
446 Student's *t*-test. (* $p < 0.05$).


447 **FIG. 4.** IFN- γ and IL-4 production by splenocytes of mice immunized with each
448 recombinant antigen. Splenocytes were isolated from mice immunized with each
449 antigen and stimulated with each antigen for 48 h. The secreted amount of IFN- γ and

450 IL-4 was quantified using mouse IFN- γ and mouse IL-4 ELISA kits, respectively.
451 Significance differences between two groups were observed statistically by Student's
452 *t*-test. (* p < 0.05, ** p < 0.01). White and black bars indicate each cytokine production
453 without the stimulation by each antigen (white bars) and with the stimulation by each
454 antigen (black bars).







IFN- γ **IL-4**